Form 13-F position report

SAB BIOTHERAPEUTICS INC COM NE

Reported by Kestra Advisory Services LLC

SABS CUSIP 78397T202 Manager CIK 0001830819

Reported 11,930 shares, unchanged from the prior quarter.

Reported value -64.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q1 2025
Shares 11,930 Quarter-end amount reported
Reported value $16,225 Fair value at quarter end
Consecutive quarters held 3 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-06-30 16000
2022-09-30 8000
2022-12-31 6489
2023-03-31 4840
2023-06-30 17430
2023-09-30 13230
2023-12-31 60500
2024-03-31 0
2024-09-30 32211
2024-12-31 45265
2025-03-31 16225
2025-06-30 20937
2025-09-30 23979
2025-12-31 43197
2026-03-31 236468
2026-06-30 194263

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for SAB BIOTHERAPEUTICS INC COM NE held by Kestra Advisory Services LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 49,811 -11,930 (-19.3%) < 0.01% $194,263 2026-07-28
Q1 2026 Added 61,741 +50,191 (434.6%) < 0.01% $236,468 2026-04-30
Q4 2025 Reduced 11,550 -380 (-3.2%) < 0.01% $43,197 2026-02-13
Q3 2025 Unchanged 11,930 0 (0.0%) < 0.01% $23,979 2025-11-14
Q2 2025 Unchanged 11,930 0 (0.0%) < 0.01% $20,937 2025-08-15
Q1 2025 Unchanged 11,930 0 (0.0%) < 0.01% $16,225 2025-05-14
Q4 2024 Unchanged 11,930 0 (0.0%) < 0.01% $45,265 2025-02-10
Q3 2024 New 11,930 +11,930 (0.0%) < 0.01% $32,211 2024-11-13
Q1 2024 Reduced 0 -88,000 (-100.0%) 0 $0 2024-05-15
Q4 2023 Added 88,000 +67,000 (319.0%) < 0.01% $60,500 2024-02-14
Q3 2023 Unchanged 21,000 0 (0.0%) < 0.01% $13,230 2023-11-13
Q2 2023 Added 21,000 +10,000 (90.9%) < 0.01% $17,430 2023-08-11
Q1 2023 Unchanged 11,000 0 (0.0%) < 0.01% $4,840 2023-05-12
Q4 2022 Unchanged 11,000 0 (0.0%) < 0.01% $6,489 2023-01-31
Q3 2022 Unchanged 11,000 0 (0.0%) < 0.01% $8,000 2022-11-01
Q2 2022 New 11,000 +11,000 (0.0%) < 0.01% $16,000 2022-08-12

Who else reported the position

30 managers reported SAB BIOTHERAPEUTICS INC COM NE for Q1 2025.

Managers reporting SAB BIOTHERAPEUTICS INC COM NE in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BVF INC IL Unchanged 917,826 0 0.05% $1,239,065 5 qtrs
Sessa Capital IM L P Unchanged 458,457 0 0.02% $623,502 5 qtrs
VANGUARD GROUP INC Added 277,510 +135 < 0.01% $374,639 5 qtrs
HB Wealth Management LLC Added 263,200 +25,800 < 0.01% $357,952 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 84,685 +4,451 < 0.01% $114,342 5 qtrs
Pathstone Holdings LLC Unchanged 50,650 0 < 0.01% $68,885 5 qtrs
BlackRock Inc Reduced 22,301 -303 < 0.01% $30,330 3 qtrs
SILVER OAK SECURITIES INCORPORATED New 20,188 +20,188 < 0.01% $29,878 1 qtr
Kovitz Investment Group Partners LLC Unchanged 19,201 0 < 0.01% $26,113 3 qtrs
First PREMIER Bank Unchanged 18,986 0 < 0.01% $26,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 14, 2025
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.